Researchers at Mayo Clinic and other major academic headache centers across the U.S. recently conducted the study that examined the effectiveness of using a single-pulse transcranial magnetic stimulation device to prevent migraine attacks. The eNeura SpringTMS Post-Market Observational U.S. Study of Migraine study, also known as ESPOUSE, instructed participants to self-administer four pulses with the device in the morning and four pulses at night over three months to prevent and treat migraine attacks as needed. Spring TMS stands for Spring transcranial magnetic stimulation or sTMS.
“The migraine brain is hyperexcitable, and basic science studies have demonstrated modulation of neuronal excitability with this treatment modality,” says Amaal Starling, M.D., a Mayo Clinic neurologist, who is first author of the study. “Our study demonstrated that the four pulses emitted from this device twice daily reduce the frequency of headache days by about three days per month, and 46 percent of patients had at least 50 percent or less migraine attacks per month on the treatment protocol. This data is clinically significant. Based on the current study and prior studies in acute migraine attack treatment, sTMS not only helps to stop a migraine attack, but it also helps prevent them.”
“For certain patients, treatment options for migraines, such as oral medications, are not effective, well-tolerated or preferred,” Dr. Starling adds. “The sTMS may be a great option for these patients and allow doctors to better meet their unique needs.”
The U.S. Food and Drug Administration already had approved the sTMS device for the acute treatment of migraine with aura. The FDA now has approved it to prevent migraine, as well.